Chunqin Deng
Overview
Explore the profile of Chunqin Deng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
612
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Weatherald J, Nathan S, El-Kersh K, Argula R, DuBrock H, Rischard F, et al.
BMJ Open Respir Res
. 2024 Mar;
11(1).
PMID: 38519114
Background: Inhaled treprostinil (iTre) is the only treatment approved for pulmonary hypertension due to interstitial lung disease (PH-ILD) to improve exercise capacity. This post hoc analysis evaluated clinical worsening and...
3.
Grunig E, Rahaghi F, Elwing J, Vizza C, Pepke-Zaba J, Shen J, et al.
Adv Ther
. 2023 Dec;
41(2):618-637.
PMID: 38055186
Introduction: In the event-driven FREEDOM-EV trial, oral treprostinil delayed clinical worsening in patients with pulmonary arterial hypertension (PAH). Open-label extension studies offer additional data about tolerability, efficacy, and survival, especially...
4.
Nathan S, Johri S, Joly J, King C, Raina A, McEvoy C, et al.
Thorax
. 2023 Nov;
79(4):301-306.
PMID: 37979971
Objective: A post-hoc analysis of the INCREASE trial and its open-label extension (OLE) was performed to evaluate whether inhaled treprostinil has a long-term survival benefit in patients with pulmonary hypertension...
5.
Nathan S, Medarov B, Ho L, Kingrey J, Hong T, Rao Y, et al.
Ann Am Thorac Soc
. 2023 Jul;
20(10):1537-1540.
PMID: 37413676
No abstract available.
6.
Waxman A, Restrepo-Jaramillo R, Thenappan T, Engel P, Bajwa A, Ravichandran A, et al.
Eur Respir J
. 2023 Apr;
61(6).
PMID: 37080567
Introduction: The 16-week randomised, placebo-controlled INCREASE trial (RCT) met its primary end-point by improving 6-min walk distance (6MWD) in patients receiving inhaled treprostinil for pulmonary hypertension due to interstitial lung...
7.
Benza R, Gomberg-Maitland M, Farber H, Vizza C, Broderick M, Holdstock L, et al.
J Heart Lung Transplant
. 2022 Sep;
41(11):1572-1580.
PMID: 36117055
Background: Risk scores integrate clinical variables emphasizing symptoms, exercise capacity, and measures of cardiac strain to predict clinical outcome better than any single value in pulmonary arterial hypertension (PAH). Risk...
8.
Nathan S, Deng C, King C, DuBrock H, Elwing J, Rajagopal S, et al.
Chest
. 2022 Sep;
163(2):398-406.
PMID: 36115497
Background: Pulmonary hypertension (PH) complicates the course of many patients with fibrotic interstitial lung disease (ILD). Inhaled treprostinil (iTre) has been shown to improve functional ability and to delay clinical...
9.
Spikes L, Bajwa A, Burger C, Desai S, Eggert M, El-Kersh K, et al.
Pulm Circ
. 2022 May;
12(2):e12063.
PMID: 35514770
Inhaled treprostinil is an approved therapy for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease in the United States. Studies have confirmed the robust benefits and...
10.
Nathan S, Tapson V, Elwing J, Rischard F, Mehta J, Shapiro S, et al.
Am J Respir Crit Care Med
. 2021 Nov;
205(2):198-207.
PMID: 34767495
The INCREASE study of inhaled treprostinil met its primary endpoint of change in 6-minute-walk distance at Week 16. In addition, there were significantly fewer clinical worsening events in patients receiving...